EN DE
Watch Talphera Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Talphera Inc. (TLPH) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Talphera Inc. stock $0.45, price $0.86, that is 47.9% below the price, quality 39 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

TI Talphera Inc. logo Thin data Nov 16, 2026

Talphera Inc.

TLPH · US

Far too expensive (fair value 48% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Low debt 
Fair value $0.4487 · Strongly overvalued 
Quality 39/100 
Falling price (downtrend) 
Weak Growth (revenue 5y −65.1 %/yr in USD) 
Negative free cash flow 
Trails peers (0/7) 
Narrow moat 6/100 · thin data
Thin data 
Estimate
Watch Talphera Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$23.40 $0.3900 Fair Value $0.4487 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range $0.3900 – $23.40 · fair‑value band $0.3365 – $0.5609 · the $0.8609 price screens above the $0.4487 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow Talphera in your weekly email

Every Wednesday you see whether Talphera is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings.

Show moreShow less

The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit.

It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and an anti-viral treatment; Fedsyra, an ephedrine pre-filled syringe for injection; and a phenylephrine pre-filled syringe for injection.

The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.

Stock analysis

Talphera Inc. (TLPH) currently trades at $0.8609, while our estimate is $0.4487, 48% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.3365 (bear) to $0.5609 (bull), the price of $0.8609 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Talphera Inc. reported revenue of $28.0K in FY2025 versus $378K in FY2021, a compound −47.8%/yr. Reported net income was −$14.3M in FY2025.

Key figures

Market cap $65.0M Micro · EPS (TTM) $−0.2600 · Return on equity −143% · Return on assets (EBIT) −55.6% (5-year average) · Operating margin −1,474,700% · Free cash flow −$11.4M · Net debt $605K.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).

What moves the price

The share trades about 41% below its 52-week high and 19% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −48%, TLPH screens richer than that median.

Fair Value

Bear $0.3365 Fair Value $0.4487 Bull $0.5609
Price $0.8609 · Downside -47.9%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 39/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 75
Are margins and returns getting better?
Cashflow 30
Do the profits arrive as real cash?
Financial strength 55
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 41
How calm the share price moves, does not count
Price momentum 24
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 9
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

  • BuyVincent J. AngottiCHIEF EXECUTIVE OFFICER, Director2× since Feb 12, 2026: 318,674 shares, avg. $0.6627$211,198Mar 13, 2026
  • BuyBadri N DasuChief Engineering Officer35,000 shares at $0.8100$28,350Feb 12, 2026
  • BuyRaffi AsadorianChief Financial Officer45,000 shares at $0.8100$36,450Feb 12, 2026
  • BuyShakil AslamChief Medical Officer35,000 shares at $0.8100$28,350Feb 12, 2026

Plus 8 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−74.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−65.1%
Start year 2020 (pandemic). Over 10 years: −48.0% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−22.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−756.3% (2020) → −48,157.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

TLPH screens overvalued: fair value 48% below the price. Compare with Merck KGaA →

Compare Talphera Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks

Beats the industry median on 0/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 39 · Bottom 25%
Fair Value upside −47.9% · Below median
Profitability
Return on assets −48.1% · Bottom 25%
Balance sheet
Debt / equity 0.29× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 3.82× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 19
FUTURE (revenue growth)0 · sector 28
PAST (return on equity)0 · sector 26
HEALTH (low debt)85 · sector 96
DIVIDEND (yield)0 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $84.39 $113.53 +35% vs TLPH
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.02 ¥53.04 +10% vs TLPH
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,868 ₹1,983 +6% vs TLPH
Haleon plc HLN $9.20 $8.47 −8% vs TLPH
Merck KGaA MRK €149.70 €108.83 −27% vs TLPH
Galderma Group GALD CHF 191.00 CHF 112.46 −41% vs TLPH
Takeda Pharmaceutical Company TAK $21.59 $11.23 −48% vs TLPH
Teva Pharmaceutical Industries Limited TEVA $42.57 $20.74 −51% vs TLPH
Sandoz Group SDZ CHF 84.60 CHF 40.54 −52% vs TLPH
Divi's Laboratories Limited DIVISLAB ₹11,080 ₹1,567 −86% vs TLPH

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Talphera Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Talphera Inc. Fair Value". https://www.fairvalue-calculator.com/stock/TLPH

Frequently asked questions

Is Talphera Inc. (TLPH) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is $0.4487 versus a price of $0.8609, about 48% lower (overvalued).
What is the fair value of TLPH?
Our estimate for Talphera Inc. is $0.4487 (as of Nov 16, 2026), built from audited fundamentals. The current price: $0.8609.
What is the quality score of TLPH?
Talphera Inc. has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Talphera Inc. (TLPH)?
Our calculated price target is the estimate of $0.4487 (as of Nov 16, 2026). Cautious scenario $0.3365, optimistic scenario $0.5609. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Talphera Inc. stock forecast for 2026?
Our estimate puts fair value at $0.4487, about 48% lower versus a price of $0.8609 (overvalued). Cautious scenario $0.3365, optimistic scenario $0.5609. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Talphera Inc. (TLPH)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Talphera Inc. it is $0.4487 per share (as of Nov 16, 2026), against a price of $0.8609.
Is Talphera Inc. stock overvalued or undervalued in 2026?
As of Nov 16, 2026, TLPH trades above its calculated fair value: price $0.8609, fair value $0.4487, a gap of about −48% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of TLPH?
No. The price is what the market pays today ($0.8609); the fair value is what the company's own numbers justify ($0.4487). For Talphera Inc. the two are $0.4122 per share apart. That gap is exactly why we show both numbers side by side.
How much is Talphera Inc. worth?
The market values Talphera Inc. at about $65.0M (market capitalisation, as of Nov 16, 2026). Per share that is $0.8609; our models calculate a fair value of $0.4487 per share.
What do the bullish and bearish scenarios say about TLPH?
Our models span a range for Talphera Inc.: cautious scenario $0.3365, base $0.4487, optimistic $0.5609 per share (as of Nov 16, 2026, price $0.8609). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Talphera Inc. (TLPH)?
Balance-sheet figures for Talphera Inc. (as of Nov 16, 2026): return on equity −143.4%, debt of 0.29 per unit of equity. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is TLPH from its 52-week high?
Talphera Inc. trades at $0.8609, about 41% below its 52-week high of $1.47 and 19% above the low of $0.7223 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $0.4487 is for.
Which stocks are comparable to Talphera Inc.?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Talphera Inc. stock attractive at the current price?
The data as of Nov 16, 2026: price $0.8609, calculated fair value $0.4487 (−48%), Quality Score 39/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Talphera Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Talphera Inc. (TLPH)?
The closing price on Nov 16, 2026 was $0.8609. Our estimate is $0.4487, about 48% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Talphera Inc. right now?
The price sits above even our optimistic bull case ($0.5609). The favourable scenario is already priced in. Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Talphera Inc.

How large is the market capitalisation of Talphera Inc. (TLPH)?
The market capitalisation of Talphera Inc. is $65.0M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Talphera Inc. (TLPH)?
Earnings per share at Talphera Inc. are $−0.2600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Talphera Inc. (TLPH)?
The return on equity (ROE) of Talphera Inc. is −143% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Talphera Inc. (TLPH)?
On an EBIT basis the return on assets of Talphera Inc. is −55.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Talphera Inc. (TLPH)?
The operating margin of Talphera Inc. is −1,474,700% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Talphera Inc. (TLPH) generate?
The free cash flow of Talphera Inc. is −$11.4M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Talphera Inc. (TLPH) carry?
The net debt of Talphera Inc. is $605K (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Talphera Inc. in the live analysis

One click puts Talphera Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.